Department of Pediatric Surgical Oncology Children's Hospitial of Chongqinng Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Children's Hospital of Chongqing Medical University, Chongqing, China.
Inflamm Res. 2024 Sep;73(9):1529-1545. doi: 10.1007/s00011-024-01914-4. Epub 2024 Jul 19.
Neuroblastoma (NB) is the most prevalent and deadliest pediatric solid tumor. With of over 50% of high-risk neuroblastoma cases relapse, the imperative for novel drug targets and therapeutic strategies is accentuated. In neuroblastoma, the existence of tumor-associated macrophages (TAMs) correlates with an unfavorable patient prognosis. However, the clinical relevance and prognostic implications of regulatory genes linked to TAMs infiltration in neuroblastoma remain unclear, and further study is required.
We conducted a comprehensive analysis utilizing transcriptome expression profiles from three primary datasets associated with neuroblastoma (GSE45547, GSE49710, TARGET) to identify hub genes implicated in immune evasion within neuroblastoma. Subsequently, we utilized single-cell RNA sequencing analysis on 17 clinical neuroblastoma samples to investigate the expression and distribution of these hub genes, leading to the identification of TNFAIP3. The above three public databases were merged to allowed for the validation of TNFAIP3's molecular functions through GO and KEGG analysis. Furthermore, we assessed TNFAIP3's correlation with immune infiltration and its potential immunotherapeutic impact by multiple algorithms. Our single-cell transcriptome data revealed the role of TNFAIP3 in macrophage polarization. Finally, preliminary experimental verifications to confirm the biological functions of TNFAIP3-mediated TAMs in NB.
A total of 6 genes related to immune evasion were screened and we found that TNFAIP3 exhibited notably higher expression in macrophages than other immune cell types, based on the scRNA-sequencing data. GO and KEGG analysis showed that low expression of TNFAIP3 significantly correlated with the activation of multiple oncogenic pathways as well as immune-related pathways. Then validation affirmed that individuals within the TNFAIP3 high-expression cohort could potentially derive greater advantages from immunotherapeutic interventions, alongside exhibiting heightened immune responsiveness. Deciphering the pseudotime trajectory of macrophages, we revealed the potential of TNFAIP3 in inducing the polarization of macrophages towards the M1 phenotype. Finally, we confirmed that patients in the TNFAIP3 high expression group might benefit more from immunotherapy or chemotherapy as substantiated by RT-qPCR and immunofluorescence examinations. Moreover, the role of TNFAIP3 in macrophage polarization was validated. Preliminary experiment showed that TNFAIP3-mediated TAMs inhibit the proliferation, migration and invasion capabilities of NB cells.
Our results suggest that TNFAIP3 was first identified as a promising biomarker for immunotherapy and potential molecular target in NB. Besides, the presence of TNFAIP3 within TAMs may offer a novel therapeutic strategy for NB.
神经母细胞瘤(NB)是最常见和最致命的小儿实体瘤。超过 50%的高危神经母细胞瘤病例复发,因此迫切需要新的药物靶点和治疗策略。在神经母细胞瘤中,肿瘤相关巨噬细胞(TAMs)的存在与患者预后不良相关。然而,与 TAMs 浸润相关的调节基因在神经母细胞瘤中的临床相关性和预后意义尚不清楚,需要进一步研究。
我们利用三个与神经母细胞瘤相关的转录组表达谱数据集(GSE45547、GSE49710、TARGET)进行了全面分析,以鉴定神经母细胞瘤中与免疫逃逸相关的枢纽基因。随后,我们利用 17 个临床神经母细胞瘤样本的单细胞 RNA 测序分析来研究这些枢纽基因的表达和分布,从而鉴定出 TNFAIP3。我们将上述三个公共数据库合并,通过 GO 和 KEGG 分析验证 TNFAIP3 的分子功能。此外,我们还通过多种算法评估了 TNFAIP3 与免疫浸润的相关性及其潜在的免疫治疗影响。我们的单细胞转录组数据揭示了 TNFAIP3 在巨噬细胞极化中的作用。最后,通过初步的实验验证来确认 TNFAIP3 介导的 TAMs 在 NB 中的生物学功能。
筛选出 6 个与免疫逃逸相关的基因,我们发现基于单细胞 RNA-seq 数据,TNFAIP3 在巨噬细胞中的表达明显高于其他免疫细胞类型。GO 和 KEGG 分析表明,TNFAIP3 的低表达与多种致癌途径以及免疫相关途径的激活显著相关。随后的验证证实,TNFAIP3 高表达队列中的个体可能从免疫治疗干预中获得更大的益处,同时表现出更高的免疫反应性。解析巨噬细胞的伪时间轨迹,我们揭示了 TNFAIP3 诱导巨噬细胞向 M1 表型极化的潜力。最后,我们通过 RT-qPCR 和免疫荧光检查证实,TNFAIP3 高表达组的患者可能从免疫治疗或化疗中获益更多。此外,TNFAIP3 在巨噬细胞极化中的作用得到了验证。初步实验表明,TNFAIP3 介导的 TAMs 抑制 NB 细胞的增殖、迁移和侵袭能力。
我们的研究结果表明,TNFAIP3 首先被鉴定为神经母细胞瘤免疫治疗的有前途的生物标志物和潜在的分子靶点。此外,TAMs 中 TNFAIP3 的存在可能为神经母细胞瘤提供一种新的治疗策略。